Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease

Figure 2 Renal morphology of tesevatinib-treated BPK kidneys. Immuno-histological analysis of BPK kidneys reveals a marked decrease in the size and number of collecting tubule cysts (stained red) following treatment with TSV at 7.5 mg/kg per day (C) and 15 mg/kg per day (D) when compared to the untreated cystic kidneys (B). Treatment of control BALB/c kidneys with TSV at 15 mg/kg per day (A) demonstrated no obvious histological abnormalities (Nephron segment-specific lectin binding of lotus tetragonolabus agglutin shows proximal tubules in brown, and binding of dolichus biflorus agglutin shows collecting tubules in red). TSV: Tesevatinib.